Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI (ciltacabtagene autoleucel) Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

27.01.2023 - Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that CARTITUDE-4, the Phase 3 study ...

Related Keywords

China ,Japan ,United States ,New Jersey ,American ,Hemophagocytic Lymphohistiocytosis ,Lida Pacaud ,American Society Of Clinical Oncology ,Janssen Biotech Inc ,Exchange Commission On ,Linkedin ,Twitter ,European Commission For The Treatment Of Patients ,Nasdaq ,Legend Biotech Corporation Stock ,Japan Ministry Of Health ,Community Register Of Orphan Medicinal Products ,Clinical Development ,American Cancer Society ,Drug Administration ,European Commission ,Medicinal Devices Agency ,Affairs At Legend Biotech ,Vice President ,Medical Affairs ,Legend Biotech ,Janssen Biotech ,Breakthrough Therapy Designation ,Drug Designation ,European Medicines Agency ,Orphan Medicinal Products ,Release Syndrome ,Effector Cell Associated Neurotoxicity Syndrome ,Macrophage Activation Syndrome ,Risk Evaluation ,Mitigation Strategy ,Nerve Palsies ,Recurrent Cytopenias ,Igg Hypersensitivity Reactions ,Use Machines ,Prescribing Information ,Boxed Warning ,Private Securities Litigation Reform Act ,Annual Report ,Exchange Commission ,Adult Patients ,Refractory Multiple ,Accessed October ,Granted Conditional Approval ,Receives Approval ,Community Register ,Orphan Medicinal ,Statistics About Multiple Myeloma ,Accessed January ,Legend Biotech Corporation ,